Get the Stockscreener App
1.72
0.58%
-0.01
After Hours:
1.66
-0.06
-3.49%
Inmed Pharmaceuticals Inc stock is traded at $1.72, with a volume of 662.84K.
It is down -0.58% in the last 24 hours and up +121.34% over the past month.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
See More
Previous Close:
$1.73
Open:
$1.77
24h Volume:
662.84K
Relative Volume:
0.42
Market Cap:
$5.70M
Revenue:
$3.25M
Net Income/Loss:
$-8.34M
P/E Ratio:
-0.6678
EPS:
-2.5755
Net Cash Flow:
$-7.71M
1W Performance:
+168.71%
1M Performance:
+121.34%
6M Performance:
+43.33%
1Y Performance:
-37.45%
1-Day Range:
$1.58
$1.99
1-Week Range:
$0.6801
$1.99
52-Week Range:
$0.575
$7.98
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Name
Inmed Pharmaceuticals Inc
Sector
Phone
(604) 669-7207
Address
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.72 | 5.73M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Stock (INM) Latest News
InMed-Mentari migraine merger backed by $290 million financing reshapes company strategy (INM) - MSN
InMed Pharmaceuticals Q3 2025 Earnings: Continued Losses as Stock DeclinesEarnings Cycle Report - Newser
InMed Pharmaceuticals Q3 2025 Earnings: Net Loss Widens Amid Pipeline FocusFree Market Insights - Newser
InMed Pharmaceuticals Shares Surge Following Mentari Merger Announcement - HarianBasis.co
ADAR1-managed funds add 468,551 InMed (INM) shares in open-market buys - Stock Titan
InMed (INM) major holder ADAR1 reports 331,449 indirect shares on Form 3 - Stock Titan
InMed Pharmaceuticals Merges with Mentari Therapeutics to Target Migraine Prevention - HarianBasis.co
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Mentari Therapeutics: $290 Million Private Placement Supports Merger With InMed Pharmaceuticals To Advance Migraine Prevention Therapies - Pulse 2.0
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested - TechStock²
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
Mentari lists via InMed merger, takes $290m for migraine pipeline - The Pharma Letter
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Th - GuruFocus
Law firm investigates InMed Pharmaceuticals' board over possible unfair sale to Mentari Therapeutics - Pluang
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewswire Inc.
Mentari, InMed Merge In Deal Backed By $290M Funding - Law360
InMed Pharmaceuticals, Inc. (INM) Stock: Climbs on $290M Private Placement and Migraine Pipeline Deal - parameter.io
InMed Pharmaceuticals and Mentari Therapeutics Announce $290M Merger to Advance Migraine Prevention Therapies - Minichart
InMed Pharmaceuticals Lowers Armistice Preferred Investment Option Exercise Price from $16.60 to $0.80 - Minichart
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
InMed amends warrant terms, cuts exercise price to $0.80 - Investing.com UK
InMed Soars 100% on $290M Migraine Deal - TechStock²
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development - GuruFocus
Trending Stocks Today | Amesite Surges 150.6% - Moomoo
InMed amends warrant terms, cuts exercise price to $0.80 By Investing.com - Investing.com South Africa
A migraine drugmaker heads to the public markets through reverse merger - BioPharma Dive
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) - Yahoo Finance
InMed (INM) agrees merger with Mentari; Mentari investors to hold ~98.5% - Stock Titan
Mentari Therapeutics to go public via InMed (NASDAQ: INM) merger - Stock Titan
InMed Pharmaceuticals stock surges on Mentari merger deal By Investing.com - Investing.com Nigeria
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline - Benzinga
INM Stock Jumps On Heavy Volume As Traders Scan Charts - StocksToTrade
InMed Pharmaceuticals stock surges on Mentari merger deal - Investing.com UK
InMed Pharmaceuticals Announces Merger with Mentari Therapeutics - Intellectia AI
INM Stock Slides As Traders Weigh Cash Runway And Steep Losses - timothysykes.com
Hehehe! Cut off the ticker symbol! And Diluted cost! Hehehe! - Moomoo
InMed and Mentari announce all-stock merger deal (INM:NASDAQ) - Seeking Alpha
InMed Pharmaceuticals InMed shareholders are expected to own approximately 1.51% of combined company - marketscreener.com
Inmed Pharmaceuticals Inmed Shareholders Are Expected To Own Approximately 1.51% Of Combined Company - TradingView
According to the latest disclosure, following the completion of the relevant transaction, the pro forma equity value of the merged company, InMed Pharmaceuticals Inc, is expected to reach approximately $421.4 million. - Bitget
Press Release: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies - Moomoo
InMed Pharmaceuticals Lowers Exercise Price on Preferred Options - TipRanks
InMed (INM) slashes Armistice option exercise price from $16.60 to $0.80 - Stock Titan
Armistice can buy 278,761 InMed shares at $0.80 after deal - Stock Titan
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update - TipRanks
TradingKey - TradingKey
Pharmaniaga Bhd. (PHARMA) - Minichart
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - Moomoo
Inmed Pharmaceuticals Inc Stock (INM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):